PMID- 20070603
OWN - NLM
STAT- MEDLINE
DCOM- 20100618
LR  - 20161125
IS  - 1399-0039 (Electronic)
IS  - 0001-2815 (Linking)
VI  - 75
IP  - 3
DP  - 2010 Mar
TI  - The role of tumor necrosis factor alpha G-308A polymorphisms in the course of 
      pulmonary sarcoidosis.
PG  - 262-8
LID - 10.1111/j.1399-0039.2009.01437.x [doi]
AB  - This study was designed to evaluate the relationship between the presence of 
      tumor necrosis factor (TNF) polymorphisms, human leukocyte antigen (HLA)-DRB1*03 
      linkage and the prognosis of sarcoidosis. In a retrospective case-control study, 
      TNF-alpha G-308A, TNF-alpha G-238A, lymphotoxin-alpha (LTA) and HLA-DRB1*03 were 
      genotyped in 625 sarcoidosis patients. These patients were classified into 298 
      patients with persistent disease and 327 patients with non-persistent disease 
      using chest X-ray (CXR) appearances and lung function parameters after at least 2 
      years of follow-up. The TNF-alpha-308A variant allele was observed in 25.5% of 
      patients with persistent disease compared with 44.0% of patients with 
      non-persistent disease. The corresponding odds ratio (OR) was 0.43 with a 95% 
      confidence interval (CI) of 0.30-0.61. A strong linkage was found between 
      TNF-alpha G-308A and HLA-DRB1*03 (OR = 0.03, 95% CI: 0.02-0.05). For TNF-alpha 
      G-238A and LTA NcoI A252G, there were no statistically significant differences in 
      the distribution of genotypes between the groups with and without persistent 
      disease. The data indicate that presence of a TNF-alpha-308A variant allele and 
      HLA-DRB1*03 were associated with a favorable prognosis. Because of the strong 
      linkage between TNF-alpha G-308A and HLA-DRB1*03, genotyping of one simple and 
      less expensive TNF-alpha single nucleotide polymorphism can be used to predict 
      the prognosis of pulmonary sarcoidosis in clinical practice.
FAU - Wijnen, P A
AU  - Wijnen PA
AD  - Department of Clinical Chemistry, Maastricht University Medical Centre, 
      Maastricht, The Netherlands.
FAU - Nelemans, P J
AU  - Nelemans PJ
FAU - Verschakelen, J A
AU  - Verschakelen JA
FAU - Bekers, O
AU  - Bekers O
FAU - Voorter, C E
AU  - Voorter CE
FAU - Drent, M
AU  - Drent M
LA  - eng
PT  - Journal Article
DEP - 20100111
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Lymphotoxin-alpha)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Alleles
MH  - Case-Control Studies
MH  - Genotype
MH  - HLA Antigens/genetics
MH  - HLA-DR Antigens/genetics
MH  - HLA-DRB1 Chains
MH  - Histocompatibility Antigens Class I/genetics
MH  - Humans
MH  - Lymphotoxin-alpha/genetics
MH  - Odds Ratio
MH  - *Polymorphism, Genetic
MH  - Polymorphism, Single Nucleotide
MH  - Radiography
MH  - Sarcoidosis/genetics
MH  - Sarcoidosis, Pulmonary/diagnostic imaging/*genetics
MH  - Tumor Necrosis Factor-alpha/*genetics
MH  - X-Rays
EDAT- 2010/01/15 06:00
MHDA- 2010/06/19 06:00
CRDT- 2010/01/15 06:00
PHST- 2010/01/15 06:00 [entrez]
PHST- 2010/01/15 06:00 [pubmed]
PHST- 2010/06/19 06:00 [medline]
AID - TAN1437 [pii]
AID - 10.1111/j.1399-0039.2009.01437.x [doi]
PST - ppublish
SO  - Tissue Antigens. 2010 Mar;75(3):262-8. doi: 10.1111/j.1399-0039.2009.01437.x. 
      Epub 2010 Jan 11.